Senolytics: Clearing Old Cells, Cautiously

Senolytics are drugs designed to kill senescent cells — cells that have stopped dividing but refuse to die, and that secrete inflammatory signals into the tissue around them. The mouse results are genuinely striking. The human results, so far, amount to a handful of small uncontrolled pilots and one randomized trial that missed its primary endpoint. Both halves of that sentence matter.

The mouse data that started it

In C57BL/6 mice already 24–27 months old — roughly a human in their eighties — intermittent oral dasatinib plus quercetin increased median post-treatment lifespan by 36% and reduced the mortality hazard by 64.9% (P = 0.01), without extending the period of disability at the end of life. That was published in Nature Medicine in 2018 and it is the finding the entire field rests on.

Hand, human, woman — illustrating Senolytics: Clearing Old Cells, Cautiously

The only randomized, controlled senolytic trial published to date — 60 postmenopausal women over 20 weeks — missed its primary endpoint. Dasatinib plus quercetin did not reduce bone resorption relative to control (−4.1% versus −7.7%, P = 0.611).

What has actually been tested in people

Study	Design	n	What it measured	Result
IPF pilot (eBioMedicine, 2019)	Open-label, single-arm, 3 weeks	14	Feasibility; physical function	6-minute walk +21.5 m (p=0.012); gait speed +0.12 m/s (p=0.024); SPPB +0.9 (p=0.003). Lung function unchanged (FVC p=0.91)
Diabetic kidney disease (eBioMedicine, 2019)	Open-label phase 1, 3 days of dosing	9	Senescent-cell burden in tissue	Adipose p16INK4a+ cells −35% (p=0.001); SA-β-gal+ cells −62% (p=0.005) at day 11
Bone metabolism (Nature Medicine, 2024)	Randomized phase 2, controlled, 20 weeks	60	Bone resorption marker CTx	No difference from control (P=0.611)
STAMINA (eBioMedicine, 2025)	Open-label, single-arm, 12 weeks	12	Feasibility; cognition, mobility	MoCA +1.0 point, not significant; no control arm

Read as a set, these say something specific. The kidney-disease study established target engagement: dasatinib plus quercetin really does reduce senescent-cell markers in human fat and skin, and it lowered circulating IL-6, IL-9, MMP-9 and MMP-12. It was not designed to show clinical benefit, and it did not.

The two uncontrolled pilots reported functional gains, and both sets of authors said the same thing about them. The pulmonary fibrosis team wrote that “without a control group, functional improvements must be interpreted with caution.” The 2025 cognition pilot stated flatly that “there was not an appropriate control group.”

The one trial that had a control arm found nothing on its primary endpoint. A secondary bone-formation marker (P1NP) rose 16% versus control at 2 and 4 weeks, then converged by week 20. An exploratory subgroup with high senescent-cell burden showed a 2.7% radius bone-density gain — a hypothesis, not a result.

Old woman, elderly, senior — illustrating Senolytics: Clearing Old Cells, Cautiously

Three reasons caution is the correct posture

The exposure base is tiny. The 2019 kidney-disease authors noted that fewer than 150 people had been treated with senolytics in clinical trials at that point, and that serious side effects “could turn out to be” real and are “not yet known.”
Dasatinib is a chemotherapy drug. Sold as Sprycel, it is approved only for Philadelphia chromosome–positive chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. Its label carries warnings for myelosuppression, bleeding events, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions and hepatotoxicity. No senolytic is approved by the FDA for aging or any age-related indication.
Senescence is not purely a defect. The same programme contributes to embryonic tissue patterning, wound healing, resolution of fibrosis and tumour suppression. Clearing it indiscriminately is not obviously free.

Hands, old, old age — illustrating Senolytics: Clearing Old Cells, Cautiously

The takeaway

Senolytics have strong preclinical evidence, demonstrated target engagement in humans, and no demonstrated clinical benefit in a controlled trial. That is an honest description of an interesting hypothesis at an early stage — not of a usable intervention. The dasatinib-plus-quercetin protocols circulating online are extrapolating from 14-, 12- and 9-person uncontrolled studies and one null RCT, using a leukemia drug. There is not enough evidence here to act on. For the biology behind the idea, see senescence and inflammaging; for the flavonoid arm of the field, see fisetin and senescence.